The Fetal Medicine Foundation 21st World Congress in Fetal Medicine, Lisbon, Portugal
Abstracts
 
  • Aneuploidies
  • Genetics
  • Defects
    • Brain
    • Face
    • Heart
    • Lungs
    • Gastrointestinal
    • Genitourinary
    • Abdominal wall
    • Spine
    • Skeleton
    • Syndrome
    • Other
  • Fetal therapy
  • Infections
  • Maternal medicine
  • Preeclampsia
  • Gestational diabetes
  • Preterm birth
  • Growth
  • Labor
  • Neurosonography
  • Obstretrics
  • Multiple pregnancies
  • Other

Preeclampsia

  1. A case of puerperial HELLP syndrome complicated by subcapsular liver hematoma View pdf
  2. A potential role of maternal dietary pattern in the development of preeclampsia View pdf
  3. Abnormal uterine artery doppler versus laterally located placenta in predicting maternal and neonatal outcomes in preeclampsia View pdf
  4. Adherence to guideline-recommended aspirin for preeclampsia prevention View pdf
  5. Aspirin at 75 to 81 mg for the prevention of preterm preeclampsia: a meta-analysis View pdf
  6. Association of genetic ancestry with preeclampsia in multi-ethnic cohorts of pregnant women View pdf
  7. Biochemical markers and preeclampsia risk View pdf
  8. Biochemical markers of cardiac dysfunction in pregnancies with hypertensive pregnancy disorders View pdf
  9. Correlation between sFlt-1/PIGF ratio levels in patients with severe range blood pressures before 34 weeks of gestation and the mean latency time until delivery View pdf
  10. Cost analysis of predicting preeclampsia by pro-and-anti angiogenic factors View pdf
  11. Cytokines and melatonin: their roles and interaction in pregnancy complicated with preeclampsia View pdf
  12. Development of a tool to assess calcium intake and identify pregnant women at risk of preeclampsia View pdf
  13. Dietary intake of ultra-processed foods and risk of preeclampsia View pdf
  14. Effect of aspirin on placental biomarkers profile in women at high-risk for preeclampsia View pdf
  15. Effect of Mediterranean diet intervention during pregnancy on maternal brain: a secondary analysis of the IMPACT BCN randomized clinical trial View pdf
  16. Effectiveness of preeclampsia screening - a six month analysis View pdf
  17. Effects of a Mediterranean diet intervention during pregnancy on the incidence of preeclampsia. The IMPACT BCN trial View pdf
  18. Effects of mediterranean diet or stress reduction interventions during pregnancy on fetal brain development assessed by MR measurements View pdf
  19. Evaluation of adherence to aspirin use in the prevention of preeclampsia View pdf
  20. Evaluation of diagnostic accuracy of sFlt-1: PlGF ratio, uric acid, and the combination of both in preeclampsia spectrum disorders: a retrospective study View pdf
  21. Evaluation of implementation of a prophylaxis protocol with aspirin 150mg/day on occurrence of preeclampsia, fetal growth restriction, and prematurity View pdf
  22. Fetal fraction of cell-free DNA in non-invasive prenatal testing and adverse pregnancy outcomes: a retrospective cohort study of 56,110 pregnant women View pdf
  23. First trimester screening program for preterm preeclampsia and aspirin prophylaxis in an Italian obstetric population View pdf
  24. First-trimester preeclampsia screening and risk of adverse pregnancy outcome View pdf
  25. Fisrt trimester screening for preeclampsia View pdf
  26. Impact of aspirin dose on the development of preeclampsia in twin pregnancy: a multicentre retrospective study with propensity score matching View pdf
  27. Impact of preeclampsia screening implementation on incidence and outcomes: a hospital-based study View pdf
  28. Implementation of first-trimester screening and prevention of preeclampsia: a stepped wedge cluster-randomised trial in Asia View pdf
  29. Increased risk of intrapartum fetal compromise in patients at high risk of preeclampsia via the Fetal Medicine Foundation algorithm who do not develop preeclampsia View pdf
  30. Influence of hypertension in pregnancy on neonatal birthweight View pdf
  31. Influence of seasonality on preeclampsia in pregnant women assisted at the maternity school of the federal university of Rio de Janeiro, Brazil View pdf
  32. Inter-manufacturer assessment of the diagnostic performance of angiogenic ratio versus glycosylated fibronectin in women with suspected preeclampsia View pdf
  33. Maternal cardiovascular hemodynamics for the prediction of preeclampsia at 12-16 weeks View pdf
  34. Maternal characteristics plus PLGF: a viable alternative approach for 1st trimester PE Screening? View pdf
  35. Measurement of endothelial dysfunction using the EndoPAT device in pregnant women with preeclampsia and fetal growth restriction View pdf
  36. Perceived partner support during pregnancy View pdf
  37. Pilot of community-based point-of-care placental growth factor testing (POC-PlGF) in Sierra Leone View pdf
  38. PlGF for aspirin discontinuation at 24-28 weeks after preeclampsia screening View pdf
  39. Postpartum medical care after preeclampsia: an observational database study up to 7.5 years after birth View pdf
  40. Predicting PE and PTD by extracellular vesicles microarray View pdf
  41. Prediction of first-trimester preeclampsia in twins by cell-free fetal DNA (cfDNA) fraction, placental growth factor (PLGF), and mean arterial pressure (MAP) View pdf
  42. Predictive Model for Preeclampsia: sFlt-1/PlGF ratio and uterine artery Doppler parameters View pdf
  43. Preeclampsia risk prediction model for Chinese pregnant women (ChiPERM): a multicentre, pragmatic, stepped-wedge cluster-randomized controlled trial View pdf
  44. Prevalence of postpartum hemorrhage in patients on asa 162mg/d for preeclampsia prevention View pdf
  45. Prevalence of preeclampsia after first trimester screening and prompt prophylaxis intervention at the State Center for Timely Prenatal Screening in León Guanajuato México View pdf
  46. Retinal findings and risk factors of preeclampsia-associated retinopathy: A retrospective cohort study View pdf
  47. Role of ophthalmic artery doppler at first trimester in the prediction of preeclampsia View pdf
  48. Screening and prevention of preeclampsia in patients with preeclampsia and eclampsia admitted to a maternity school in Campina Grande-PB View pdf
  49. SFlt-1/PlGF ratio in the prediction of preeclampsia in women with diabetic kidney disease (DKD) View pdf
  50. SFlt/PLGF ratio as a biomarker for adverse maternal and fetal outcomes in hypertensive disorders of pregnancy: an ambispective analysis View pdf
  51. StopPRE trial: effect of aspirin discontinuation on the trajectories of biophysical and biochemical markers View pdf
  52. Study protocol for the stepped wedge cluster randomized controlled trial: preeclampsia prevention in denmark (prepred) View pdf
  53. The association of IL-17 and PlGF/sENG ratio in preeclampsia and adverse pregnancy outcomes View pdf
  54. The association of severe preeclampsia/eclampsia with adverse maternal and foetal outcomes in Somali women: a cross-sectional study View pdf
  55. The impact of introducing aspirin before ultrasound at 11-14 weeks in women with previous preeclampsia View pdf
  56. The prediction model for stillbirth based on first trimester preeclampsia combined screening View pdf
  57. The use of soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) in differential diagnosis in psychiatric patient suffering from catatonia suspected from eclamptic seizure View pdf
  58. Timing of a combined first trimester blood-test in screening for chromosomal aberrations and preeclampsia View pdf
  59. Uterine artery doppler following first-trimester preeclampsia screening View pdf
  60. Validation of the Full-PIERS model in predicting adverse maternal outcomes in patients with severe early onset preeclampsia in a second level Hospital in the Northeast of Mexico View pdf
623362726135652256936173673266246800627656646112678363616227670662666154613767236645615566876507643562016419612765146666665160856109626866396458619760765665620263136190617860986646631563036787622162856103651556916669619964386119651060755650
© 2024 The Fetal Medicine Foundation